Bildkälla: Stockfoto

Curasight Q2: Strategic progress - Redeye

Redeye updates its view of Curasight following the Q2 report and recent events in the company, including an announced financing solution and progress with uTRACE in prostate cancer.

Redeye updates its view of Curasight following the Q2 report and recent events in the company, including an announced financing solution and progress with uTRACE in prostate cancer.
Börsvärldens nyhetsbrev
ANNONSER